Obesity: A new paradigm for treating obesity and diabetes mellitus

Nature Reviews Endocrinology

Volumn 11, Issue 4, 2015, Pages 196-198

  Scheen, André J ^a   Paquot, Nicolas ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR; INCRETIN; INSULIN; PEPTIDE;

BARIATRIC SURGERY; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; DIABETES MELLITUS; METABOLISM;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; PEPTIDES;

EID: 84925850835     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.3     Document Type: Short Survey

References (10)

1. Scheen, A. J. & Van Gaal, L. F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2, 911-922 (2014).
2. Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015).
3. Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425-433 (2013).
4. Neumiller, J. J. Incretin-based therapies. Med. Clin. North Am. 99, 107-129 (2015).
5. Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837 (2013).
6. Unger, R. H. & Cherrington, A. D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4-12 (2012).
7. Lund, A., Bagger, J. I., Christensen, M., Knop, F. K. & Vilsbøll, T. Glucagon and type 2 diabetes: the return of the α cell. Curr. Diab. Rep. 14, 555 (2014).
8. Arafat, A. M. et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia 57, 2108-2116 (2014).
9. Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131-1138 (2013).
10. Cegla, J. et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63, 3711-3720 (2014).